AMEX · MTNB
Healthcare · Biotechnology
$2.64
Up+$0.22 (+9.09%)
Updated Oct 4, 2026, 6:27 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · MTNB
1M range · 19 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
MTNB closed at $2.64 after 19 trading sessions, up 1350.55% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $2.53 | $2.7479 | $2.4208 | $2.64 | 295.5K |
| Oct 1, 2026 | $2.58 | $2.58 | $2.36 | $2.42 | 45.16K |
| Sep 30, 2026 | $2.72 | $2.80 | $2.4441 | $2.55 | 152.6K |
| Sep 29, 2026 | $2.47 | $3.0499 | $2.40 | $2.88 | 764.31K |
| Sep 28, 2026 | $2.47 | $2.65 | $2.34 | $2.53 | 117.84K |
| Sep 25, 2026 | $2.58 | $2.643 | $2.313 | $2.40 | 52.01K |
| Sep 24, 2026 | $2.625 | $2.685 | $2.568 | $2.67 | 15.75K |
| Sep 23, 2026 | $2.6625 | $2.6775 | $2.514 | $2.625 | 28.15K |
| Sep 22, 2026 | $2.6025 | $2.6955 | $2.55 | $2.655 | 13.72K |
| Sep 21, 2026 | $0.16 | $0.1749 | $0.16 | $0.1739 | 292.4K |
| Sep 18, 2026 | $0.1633 | $0.169 | $0.158 | $0.1604 | 426.6K |
| Sep 17, 2026 | $0.158 | $0.1638 | $0.1549 | $0.163 | 674.34K |
| Sep 16, 2026 | $0.1612 | $0.1698 | $0.1552 | $0.1651 | 1.08M |
| Sep 15, 2026 | $0.1903 | $0.1928 | $0.1505 | $0.16 | 1.39M |
| Sep 14, 2026 | $0.19 | $0.1965 | $0.1842 | $0.192 | 2.01M |
| Sep 11, 2026 | $0.19 | $0.20 | $0.18 | $0.185 | 800.49K |
| Sep 10, 2026 | $0.1862 | $0.205 | $0.1811 | $0.205 | 1.66M |
| Sep 9, 2026 | $0.182 | $0.1873 | $0.1816 | $0.1837 | 640.27K |
| Sep 8, 2026 | $0.1886 | $0.19 | $0.1803 | $0.182 | 566.66K |
The latest Smart Investors Daily articles mentioning MTNB.
Company
Market Activity
Research & News
MTNB research
Company profile and research snapshot.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 31, 2024 | Maxim Group | Hold | — |
| Oct 11, 2023 | BTIG | Buy | — |
| Jan 31, 2023 | HC Wainwright & Co. | Buy | — |
| Aug 13, 2020 | Aegis Capital | Buy | — |
| Jan 27, 2020 | Piper Sandler | Overweight | — |
No generated briefing is available yet.
Benzinga · Sep 16, 2026
On June 23, 2025, at the 2025 annual meeting of stockholders of Matinas BioPharma Holdings, Inc. (the "Company"), the stockholders approved the authorization of the Board of Directors (the "Board"), in
Yahoo · Sep 14, 2026
Agreement establishes GH Power’s first commercial hydrogen offtake and validates hydrogen production from the Company’s proprietary aluminum-water reactor platformToronto, Canada, Sept. 14, 2026 (GLOBE NEWSWIRE) -- GH Power Inc. (“GH Power” or the “Company”) (NYSE American: MTNB), a Canadian clean energy and critical materials technology company, today announced that it has entered into a multi-year hydrogen supply agreement (the “Agreement”) with Change Energy Engineering Inc. on behalf of its
Yahoo · Sep 4, 2026
BEDMINSTER, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on August 31, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $2.
Benzinga · Aug 20, 2026
Gainers Circle8 Group (NASDAQ:CIRC) shares increased by 18.2% to $0.77 during Thursday's pre-market session. The company's market cap stands at $60.1 million. The company's, Q2 earnings came out yesterday.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MTNB.
